Document:

exv10w10

Exhibit 10.10

RXI PHARMACEUTICALS CORPORATION

SCIENTIFIC ADVISORY AGREEMENT

This Scientific Advisory Agreement (the “Agreement”) dated as of April 13, 2011, is made by Dr.
George E. Peoples (the “Advisor”) and RXi Pharmaceuticals Corporation, a Delaware corporation
(“RXi” and together with the Advisor, the “Parties”).

AGREEMENT

1. Services. As of the Effective Date, RXi shall retain the Advisor, and the Advisor agrees to
serve, as a scientific advisor to RXi and to consult with RXi in the Field (as hereinafter
defined). The Advisor agrees to provide to RXi such services in the Field as are customarily
performed by a scientific advisor to a company such as RXi (the “Services”). The Advisor is being
engaged by RXi as a consultant for the exchange of ideas only and shall not direct or conduct
research for or on behalf of RXi. The Services will include, without limitation:

	 	•	 	Consulting with RXi’s management within the Advisor’s professional area of
expertise from time to time as reasonably requested by RXi;
	 
	 	•	 	Exchanging strategic and business development ideas with RXi;
	 
	 	•	 	Chairing the Scientific Advisory Board (SAB); and
	 
	 	•	 	Attending scientific, medical, regulatory or business meetings with RXi’s
management, such as United States Food & Drug Administration meetings, meetings
with strategic or potential strategic partners and other meetings relevant to the
Advisor’s area of expertise.

For purposes of this Agreement, the term “Field” means the development of pharmaceutical products
or product candidates for the treatment of HER2-positive cancer, or may directly compete with
NeuVax. The Advisor is agreeing to provide the Services under this Agreement in consideration of
the compensation provided in Section 3 hereof. During the Term of this Agreement, without the
prior written consent of RXi, the Advisor will not be employed by or otherwise render services to
another company engaged in the Field.

2. Performance of Services. As of the Effective Date, the Advisor agrees to make himself available
to render the Services, at such time or times and location or locations as may be mutually agreed,
from time to time at the request of RXi. The Advisor agrees not to perform any Services for RXi on
the premises of his current employer, US Army (which is referred to as the “Principal
Institution”), any academic institution or any hospital with which he is or may become affiliated
(each such Principal Institution, academic institution and hospital an “Affiliated Institution”) or
with the respective facilities or funds of any such Affiliated Institution which could result in
claims by such Affiliated Institution of rights in any Inventions (as defined in Section 7 hereof
), without the express prior agreement of RXi and the Affiliated Institution, as appropriate.
Unless covered by an appropriate agreement between any third party (other than an Affiliated
Institution) and RXi, the Advisor shall not knowingly engage in any activities or use any
facilities in the course of providing Services which could result in claims of ownership to any
Inventions being made by such third party. The Advisor agrees to devote his reasonable and
diligent efforts to the performance of the Services.

 

 

3. Compensation. RXi will compensate the Advisor for providing the Services to RXi as follows,
with such compensation to be the full consideration for the Services:

     (A) Cash Compensation. The Advisor will receive an up-front $50,000 retainer fee and a
monthly consulting fee of $15,000 during the Term, payable on the last day of each calendar month
and pro rated for each partial month of engagement hereunder.

     (B) Stock Option. On the Effective Date, the Company shall grant the Advisor a stock
option (“Option”) under the Company’s Amended and Restated 2007 Incentive Plan (the
“Plan”) to purchase One Hundred Thousand (100,000) shares of the Company’s common stock.
The Option shall vest in equal quarterly installments over 3 years beginning on the first quarterly
anniversary of the Effective Date, provided, in each case, that the Advisor remains in the
continuous engagement of the Company through such quarterly anniversary date. The Option shall (a)
be exercisable at an exercise price per share equal to the closing market price of the Company’s
common stock on the date of the grant, (b) have a term of ten years, and (c) be on such other terms
as shall be determined by the Board (or the Compensation Committee of the Board) and set forth in a
customary form of stock option agreement under the Plan evidencing the Option.

     (C) Expenses. RXi shall promptly reimburse the Advisor for reasonable out-of-pocket expenses,
including, without limitation, travel expenses incurred by him in the performance of the Services,
following RXi’s receipt of a request for reimbursement from the Advisor. The Advisor shall provide
RXi with documentation supporting all such expenses within 30 days of incurring the expense.

4. Principal Institution. RXi recognizes that the activities of the Advisor are or will be subject
to the rules and regulations of the Principal Institution and any other Affiliated Institution, now
or in the future, and RXi agrees that the Advisor shall be under no obligation to perform Services
if such performance would conflict with such rules and regulations, or constitute a conflict of
interest under the relevant policies of the Affiliated Institution. The Advisor has no reason to
believe that the Advisor’s performance of any of the services contemplated by this Agreement will
conflict with the applicable rules or policies of any Affiliated Institution, each as presently in
effect. In the event such rules and regulations shall, in RXi’s reasonable opinion or the
reasonable opinion of the Advisor, substantially interfere with the performance of Services by the
Advisor, RXi or the Advisor may, notwithstanding anything herein to the contrary, terminate this
Agreement without liability to the other party upon 30 days notice. The Advisor shall provide
copies to RXi of all status reports he delivers and other material correspondences he has with any
Affiliated Institution concerning this Agreement or the Services within three (3) business days of
his delivery or receipt of such report or correspondence, provided that the policies of any
Affiliated Institution permit him to do so, and provided further that RXi agrees to hold any such
report or correspondence in confidence.

5. Term; Termination; Effect of Termination.

     (A) Term; Termination. The Advisor’s performance of Services shall commence on the Effective
Date and shall continue until terminated pursuant to the terms of this Agreement (the “Term”).
Either party may terminate this Agreement by providing 30 days’ written notice to the other party.
In addition, RXi may terminate this Agreement (in addition to any other available

-2-

 

remedy) at any time for Cause. The term “Cause” shall mean the Advisor’s material breach of
this Agreement which goes uncured for more than 15 days following written notice from RXi, the
Advisor’s conviction of or plea of no contest to any felony, or the Advisor’s act or failure to act
that materially and adversely affects the business or reputation of RXi.

     (B) Effect of Termination. Upon termination of this Agreement, the Advisor shall be entitled
to payment, not later than three (3) business days after the date of termination, of (i) any
accrued but unpaid portion of his monthly consulting fee, prorated for any partial month of service
prior to the date of termination, and (ii) reimbursement of out-of-pocket expenses accrued but
unpaid as of the date of termination.

     (C) Survival of Certain Provisions. No termination of this Agreement shall relieve the
Advisor or RXi of any obligations hereunder which by their terms are intended to survive the
termination of the Advisor’s association with RXi, including, but not limited to, the obligations
of Sections 3 (as to only those provisions that are specifically described as being applicable
after the Term), 7 through 11, 14, 17, 18, and 21 through 23 hereof.

     (D) Return of RXi Property. Upon termination of this Agreement for any reason, the Advisor
shall promptly deliver to RXi any and all property of RXi or their customers, licensees, licensors,
or affiliates provided to the Advisor pursuant to this Agreement which may be in his possession or
control, including without limitation, products, memoranda, notes, diskettes, records, reports,
laboratory notebooks, or other documents or photocopies of the same and shall destroy any
Confidential Information (as defined in Section 8 hereof ) in tangible form.

6. Independent Contractor. For purposes of this Agreement and all Services to be provided
hereunder, Advisor shall not be considered a partner, co-venturer, agent, employee or
representative of Company, but shall remain in all respects an independent contractor, and neither
party shall have any right or authority to make or undertake any promise, warranty or
representation, to execute any contract, or otherwise to assume any obligation or responsibility in
the name of or on behalf of the other party. Without limiting the generality of the foregoing,
Advisor shall not be considered an employee of Company for purposes of any state or federal laws
relating to unemployment insurance, social security, workers compensation or any regulations which
may impute an obligation or liability to Company by reason of an employment relationship. Advisor
agrees to pay all income, FICA, and other taxes or levies imposed by any governmental authority on
any compensation that Advisor receives under this Agreement. Advisor shall indemnify, defend and
hold harmless Company and its officers and employees from and against any and all losses, damages,
liabilities, obligations, judgments, penalties, fines, awards, costs, expenses and disbursements
(including without limitation, the costs, expenses and disbursements, as and when incurred, of
investigating, preparing or defending any claim, action, suit, proceeding or investigation)
suffered or incurred by Company as a result of any allegation that Advisor is an employee of
Company by virtue of performing any work for or on behalf of Company hereunder or otherwise.

7. Inventions. The Advisor shall promptly disclose to RXi, and, subject to the terms of the third
paragraph of this Section 7, hereby assigns and agrees to assign to RXi (or as otherwise directed
by RXi), his full right, title and interest, if any, to all Inventions (as defined below). The
Advisor agrees to cooperate fully with RXi, its attorneys and agents, in the preparation and filing

-3-

 

of all papers and other documents as may be required to perfect RXi’ s rights in and to any of such
Inventions, including, but not limited to, execution of any and all applications for domestic and
foreign patents, copyrights or other proprietary rights and the performance of such other acts
(including, among others, the execution and delivery of instruments of further assurance or
confirmation) requested by RXi to assign the Inventions to RXi and to permit RXi to file, obtain
and enforce any patents, copyrights or other proprietary rights in the Inventions, all at RXi’s
sole cost and expense. The Advisor hereby designates RXi as his agent, and grants to RXi a power
of attorney with full power of substitution, which power of attorney shall be deemed coupled with
an interest, for the purpose of effecting any such assignment hereunder from the Advisor to RXi in
the event the Advisor should fail or refuse to sign and deliver any document in connection with
perfecting the foregoing rights of RXi within 10 days following RXi’s request; provided that, in
each case in which RXi intends to exercise this right (i) it shall give the Advisor 30 days written
notice, by certified mail that they intend to exercise their rights under this sentence, which
notice shall refer to this Agreement and shall be accompanied by (a) copies of the documents that
RXi intends to execute or file, or a description of the other acts that Companies intend to take,
and (b) reasonably sufficient information about the Invention or other intellectual property to
which the documents or acts relate for the Advisor to make a determination of whether the document
or acts relate to an Invention; and (ii) RXi may not exercise its rights under this sentence if the
Advisor notifies RXi within the 30-day period referred to above that the Advisor disagrees.

     “Inventions” shall mean, for purposes of this Section 7, ideas, discoveries, creations,
manuscripts and properties, innovations, improvements, know-how, inventions, trade secrets,
apparatus, developments, techniques, methods, biological processes, cell lines, laboratory
notebooks and formulas (whether or not patentable or copyrightable or constituting trade secrets)
conceived, made or discovered by the Advisor (whether alone or with others) within the Field (i)
solely as a direct result of consulting with RXi under this Agreement and (ii) not in the course of
the Advisor’s activities as an employee of Principal Institution. In no event shall the Advisor’s
obligations hereunder relate to any right, title or interest that the Advisor may have in ideas,
discoveries, creations, manuscripts and properties, innovations, improvements, know-how,
inventions, trade secrets, apparatus, developments, techniques, methods, biological processes, cell
lines, laboratory notebooks and formulas (whether or not patentable or copyrightable or
constituting trade secrets) conceived, made or discovered by the Advisor (whether alone or with
others) with the use of facilities or findings of any Affiliated Institution and that the Advisor
is required to assign to his Affiliated Institution pursuant to the rules and regulations of such
Affiliated Institution. Further, RXi will have no rights by reason of this Agreement in any
publication, invention, discovery, improvement, or other intellectual property whatsoever, whether
or not publishable, patentable, or copyrightable, which is developed as a result of a program of
research financed, in whole or in part, by funds provided by or under the control of the Principal
Institution. The Advisor agrees to not knowingly use or incorporate any third party proprietary
information into any Inventions or to disclose such information to RXi. Upon termination of this
Agreement with RXi, the Advisor shall provide to RXi in writing a full, signed statement of all
Inventions in which the Advisor participated prior to termination of this Agreement.

     RXi acknowledges and agrees that it will enjoy no priority or advantage as a result of the
consultancy created by this Agreement in gaining access, whether by license or otherwise, to any

-4-

 

proprietary information or intellectual property that arises from any research undertaken by
the Advisor in his capacity at the Principal Institution.

8. Confidentiality. The Advisor may disclose to RXi any information that the Advisor would
normally freely disclose to other members of the scientific community at large, whether by
publication, by presentation at seminars, or in informal scientific discussions. However, the
Advisor shall not disclose to RXi information that is proprietary to Principal Institution and is
not generally available to the public other than through formal technology transfer procedures.

     During the Term, the Advisor will be exposed to certain information concerning RXi’s research,
business, Inventions, products, proposed new products, designs, clinical testing programs,
manufacturing processes and techniques, customers, and other information and materials that embody
trade secrets or technical or business information that is confidential and proprietary to RXi and
is not generally known to the public (collectively, “Confidential Information”). Confidential
Information shall not include information that (i) is in the public domain on the Effective Date of
this Agreement, (ii) is or was disclosed to the Advisor by a third party having no fiduciary
relationship with RXi and having no known obligation of confidentiality with respect to such
information, (iii) is or was independently known or developed by the Advisor without reference to
the Confidential Information as reasonably demonstrated by the Advisor by written records or (iv)
is required by law or in a legal proceeding to be disclosed, provided that the Advisor shall give
RXi prior written notice of such proposed disclosure so that RXi may take such legal steps as they
deem appropriate to protect the Confidential Information. In addition, Confidential Information
does not include information generated by the Advisor, alone or with others, unless the information
(i) is generated solely as a direct result of the performance of the Services and (ii) is not
generated in the course of the Advisor’s activities as an employee of Principal Institution. The
Advisor hereby agrees, for a period of seven (7) years following the expiration or earlier
termination of this Agreement not to disclose or make use of, or allow others to use, any
Confidential Information, except to RXi’s employees and representatives, without RXi’s prior
written consent, unless such information becomes publicly available through no fault of the
Advisor. In addition, the Advisor further agrees not to make any notes or memoranda relating to
the business of RXi other than for the benefit of RXi and not to use or permit to be used at any
time any such notes or memoranda other than for the benefit of RXi.

9. Injunctive Relief. The Advisor agrees that any breach of this Agreement by him could cause
irreparable damage to RXi and that in the event of such breach RXi shall have the right to obtain
injunctive relief, including, without limitation, specific performance or other equitable relief to
prevent the violation of his obligations hereunder. It is expressly understood and agreed that
nothing herein contained shall be construed as prohibiting RXi from pursuing any other remedies
available for such breach or threatened breach, including, without limitation, the recovery of
damages by RXi.

10. No Assignment by the Advisor. The Services to be rendered by the Advisor are personal in
nature. The Advisor may not assign or transfer this Agreement or any of his rights or obligations
hereunder. In no event shall the Advisor assign or delegate responsibility for actual performance
of the Services to any other natural person.

-5-

 

11. Publications. The Advisor agrees that he will not at any time during the time limitations set
forth in paragraph 9 hereof, publish any Confidential Information that becomes known to him as a
result of his relationship with RXi which is, or pursuant to the terms hereof becomes, the property
of RXi or any of its clients, customers, consultants, licensors, licensees, or affiliates except
to such extent as may be necessary in the ordinary course of performing in good faith his duties as
scientific advisor of RXi and with the prior written consent of RXi.

     During the Term and for a period of two years thereafter, the Advisor agrees to submit to RXi
for a period of at least 30 days (the “Review Period”) a copy of any proposed manuscript or other
materials to be published or otherwise publicly disclosed by the Advisor (each a “Proposed
Publication”) which contains Confidential Information or discloses Inventions in sufficient time to
enable RXi to determine if patentable Inventions or Confidential Information would be disclosed.
Nothing herein shall be construed to restrict the Advisor’s right to publish material which does
not contain Confidential Information. Following the expiration of the Review Period, if RXi does
not notify the Advisor that the Proposed Publication discloses patentable Inventions or
Confidential Information such Proposed Publication shall be deemed to be approved by RXi for
publication. In addition, the Advisor will cooperate with RXi in this respect and will delete from
the manuscript or other disclosure any Confidential Information if requested by RXi and will assist
RXi in filing for patent protection for any patentable Inventions prior to publication or other
disclosure.

12. No Conflicting Agreements. The Advisor represents and warrants, that as of the Effective Date,
he will not be a party to any future commitments or obligations that conflict with this Agreement.
In this regard, as a condition to the effectiveness of this Agreement the Advisor shall provide to
RXi the written consent and acknowledgement of Principal Institution to Advisor’s entry into this
Agreement. During the Term, the Advisor will not enter into any agreement either written or oral
in conflict with this Agreement and will arrange to provide Services under this Agreement in such a
manner and at times that such Services will not conflict with his responsibilities under any other
agreement, arrangement or understanding or pursuant to any employment relationship he has at any
time with any third party. In the event of any inconsistency between this Agreement and any
agreement or policy of any Affiliated Institution, the agreement or policy of the Affiliated
Institution shall control.

13. Other Consulting Services. RXi agrees that the Advisor may serve as a member of scientific
advisory boards or in a similar capacity with, and provide consulting services to, other companies
in scientific areas outside of the Field, provided that such service does not conflict or
materially interfere with his Services hereunder.

14. Nonsolicitation. During the Term and for a period of one year thereafter, the Advisor,
personally, will not, without RXi’s prior written consent, directly solicit the employment of any
employee of RXi or its affiliates with whom the Advisor has had contact in connection with the
relationship arising under this Agreement. Nothing in this Section 14 shall be deemed to prohibit
general solicitations of employment by any Affiliated Institution.

15. Disclosure of Relationship. The parties each shall be entitled to disclose that the Advisor is
serving as a scientific advisor to RXi and RXi may use the Advisor’s name, including in any
business plan, press release, advertisement, prospectus or other offering document of RXi or its
affiliates, so long as any such usage (a) is limited to reporting factual events or occurrences
only,

-6-

 

and (b) is made in a manner that could not reasonably constitute a specific endorsement by the
Advisor of RXi or of any program, product or service of RXi. However, RXi shall not use the
Advisor’s name in any press release, or quote the Advisor in any RXi materials (including
advertisements), or otherwise use the Advisor’s name in a manner not specifically permitted by the
preceding sentence, unless in each case RXi obtains in advance the Advisor’s consent. The
foregoing consents shall not be unreasonably withheld or delayed by the Advisor. Notwithstanding
the foregoing, if, in the opinion of RXi’s counsel, RXi is required by applicable law to use the
Advisor’s name in a press release or governmental filing and, under the circumstances, RXi is not
reasonably able to obtain the advance written consent of the Advisor, as applicable, to such use,
then RXi may proceed without obtaining the advance written consent of the Advisor.

16. Notices. All notices and other communications hereunder shall be delivered or sent by
facsimile transmission, recognized courier service, registered or certified mail, return receipt
requested.

If to RXi:

RXi Pharmaceuticals Corporation

60 Prescott Street

Worcester, MA 01605

Attn: Chief Executive Officer

Facsimile: 508-767-3862

If to the Advisor:

George Peoples, M.D.

120 Geneseo Road

San Antonio, TX 78209

210-824-0617

     Such notice or communication shall be deemed to have been given as of the date sent by the
facsimile or delivered to a recognized courier service, or three days following the date sent by
registered or certified mail.

17. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the
parties and their respective legal representatives, successors and permitted assigns. The Advisor
agrees that RXi may assign this Agreement, in whole but not in part, to any purchaser of all or
substantially all of its assets or to any successor corporation resulting from any merger,
consolidation or other reorganization of RXi with or into such corporations. RXi also may assign
this Agreement, in whole but not in part, to any person or entity controlled by, in control of, or
under common control with, RXi, if it obtains the prior written consent of the Advisor, which
consent shall not unreasonably be withheld or delayed; provided, however, that no such assignment
shall relieve RXi of its liability to the Advisor hereunder. RXi may not otherwise assign this
Agreement without the Advisor’s prior written consent.

-7-

 

18. Indemnification. RXi shall indemnify, defend and hold harmless the Advisor from any claim,
loss, liability or expense (including reasonable attorney’s fees) incurred by him as a result of
the performance of his Services hereunder in accordance with the terms hereof, a material breach by
RXi hereof or any gross negligence or willful misconduct by RXi or its respective officers or
directors in connection with this Agreement or otherwise relating to or resulting from the
performance of the Services hereunder, except where such claim, loss, liability or expense is
attributable primarily to the Advisor’s own gross negligence or willful misconduct.

19. Entire Agreement; Counterparts. This Agreement constitutes the entire agreement among the
parties as to the subject matter hereof. No provision of this Agreement shall be waived, altered
or cancelled except in writing signed by the party against whom such waiver, alteration or
cancellation is asserted. This Agreement may be executed in one or more counterparts, and by
different parties hereto on separate counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

20. Governing Law. This Agreement shall be governed by and construed in accordance with the
internal laws of the State of Delaware, without regard to conflict of law principles.

21. Enforceability. The invalidity or unenforceability of any provision hereof as to an obligation
of a party shall in no way affect the validity or enforceability of any other provision of this
Agreement, provided that if such invalidity or unenforceability materially adversely affects the
benefits the other party reasonably expected to receive hereunder, that party shall have the right
to terminate this Agreement. Moreover, if one or more of the provisions contained in this
Agreement shall for any reason be held to be excessively broad as to scope, activity or subject so
as to be unenforceable at law, such provision or provisions shall be construed by limiting or
reducing it or them, so as to be enforceable to the extent compatible with the applicable law as it
shall then appear.

22. Construction. This Agreement has been prepared jointly and shall not be strictly construed
against any party.

23. Resolution of Disputes. Except as set forth below, any dispute arising under or in connection
with any matter related to this Agreement or any related agreement shall be resolved exclusively by
arbitration. The arbitration will be in conformity with and subject to the applicable rules and
procedures of the American Arbitration Association. All parties agree to be (i) subject to the
jurisdiction and venue of any arbitration or litigation in Delaware; and (ii) bound by the decision
of the arbitrator as the final decision with respect to any dispute that is to be resolved by
arbitration pursuant to this Agreement.

24. Advice of Counsel. Each party acknowledges that, in executing this Agreement, such party has
had the opportunity to seek the advice of independent legal counsel, and has read and understood
all of the terms and provisions of this Agreement.

-8-

 

     IN WITNESS WHEREOF, the parties hereto have duly executed this Scientific Advisory Agreement
as a sealed instrument as of the date first written above.

	 	 	 	 	 
	 	RXi Pharmaceuticals Corporation

 	 
	 	By:  	/s/ Mark J. Ahn
 	 
	 	 	Name:  	Mark J. Ahn, Ph.D. 	 
	 	 	Its:  	President & Chief Executive Officer
	 
	 	Advisor:

 	 
	 	/s/ George E. Peoples
 	 
	 	George E. Peoples, M.D. 	 
	 	 	 
	 

-9-exv10w11

Exhibit 10.11

[Form of] Amendment to Stock Options

Granted Under RXi Pharmaceuticals Corporation 2007 Incentive Plan

     This Amendment to Stock Options, dated as of April __, 2011, is made between RXi
Pharmaceuticals Corporation, a Delaware corporation (the “Company”) and the undersigned (the
“Holder”).

     WHEREAS, the Holder is the holder of options issued pursuant to the Company’s 2007 Incentive
Plan (the “Plan”) to purchase shares of the Company’s common stock, $0.0001 par value (the “Common
Stock”); and

     WHEREAS, the Holder and the Company have agreed to amend all options issued under the Plan to
purchase shares of Common Stock held by the Holder as of the date hereof (the “Options”) in the
manner set forth herein;

     NOW THEREFORE, for good and valuable consideration, the Company and the Holder hereby agree as
follows:

     Notwithstanding anything to the contrary set forth in any applicable option agreement, award
or certificate relating to the Options, no Option shall be exercisable unless and until the
Company’s Certificate of Incorporation has been amended to increase the number of authorized shares
of Common Stock to a number that is sufficient to permit the exercise or conversion in full of all
then outstanding options (including the Options), warrants and other securities of the Company that
are convertible into shares of Common Stock, and each Option shall thereafter be exercisable in
accordance with the terms of each such Option.

     Except as modified hereby, each Option shall continue in accordance with its terms.

     This Amendment to Stock Options may be executed in counterparts, which together shall
constitute a single instrument.

[Remainder of page intentionally left blank]

 

 

     This Amendment to Stock Options is executed as of the date first written above.

	 	 	 	 	 
	 	RXi Pharmaceuticals Corporation:

 	 
	 	By:  	 	 
	 	 	Mark Ahn, Chief Executive Officer 	 
	 	 	 	 
	 
	 	Holder:

 	 
	  	 	 	 
	 	Name:  	 
	 	 	 	 
	 

-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]